An Extension Study of an Investigational Drug, Lumasiran (ALN-GO1), in Participants With Primary Hyperoxaluria Type 1
Clinical trial NCT03350451 · COMPLETED
Trial details
- NCT number
- NCT03350451
- Sponsor
- Alnylam Pharmaceuticals
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2018-04-04
- Primary completion
- 2023-02-07
- Enrollment
- 20
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.